Effect of preventive treatment on health-related quality of life in episodic migraine

被引：23

作者：

Bordini C.A. ^{[1
]}

da Silva H.M. ^{[1
]}

Garbelini R.P. ^{[1
]}

Teixeira S.O. ^{[1
]}

Speciali J.G. ^{[1
]}

机构：

[1] Department of Neurology, São Paulo University, School of Medicine at Ribeirão Preto, 14049-900 Ribeirão Preto, SP

来源：

The Journal of Headache and Pain | 2005年 / 6卷 / 5期

关键词：

Headache; Health-related quality of life; Migraine; Preventive treatment; SF-36;

D O I：

10.1007/s10194-005-0233-7

中图分类号：

学科分类号：

摘要：

The purpose of our study was to prospectively evaluate the impact of preventive drug treatment on the quality of life of patients with episodic migraine (EM). Quality of life evaluations can enhance traditional measures of therapeutic efficacy. Thirty-five consecutive EM without aura patients attending a tertiary care unit (Batata is Headache Clinic) entered the study. They were given a prescription for preventive medication and completed the validated Portuguese version of the generic instrument Short Form-36 (SF-36) questionnaire. Six months later, patients were given another SF-36. We compared the pre-treatment and post-treatment scores for the SF-36 and analysed the headache diaries. The mean age of the 35 patients (32 women and 3 men) was 40.2 years (range 18-60 years). All 35 patients completed the pretreatment and follow-up SF-36. The pre-treatment and post-treatment mean frequency of migraine attacks was 9.16 and 2.4 crises per month, respectively (p<0.05). After the six months of preventive treatment, six of the eight domains evaluated by the SF-36 (role physical, bodily pain, general health, vitality, social function and mental health) showed statistically significant (p<0.05) improvement. The preventive treatment of migraine leads to a significant improvement in the quality of life of patients with EM. This improvement was measurable by the general quality of life instrument SF-36. © Springer-Verlag Italia 2005.

引用

页码：387 / 391

页数：4

共 27 条

[1]

Lipton R.B., Hamelsky S.W., Stewart W.F., Epidemiology and impact of headache, Wolff's Headache and Other Head Pain, pp. 85-107, (2001)

[2]

Osterhaus J.T., Townsend R.J., Gandek B., Ware Jr. J.E., Measuring the functional status and well-being of patients with migraine headache, Headache, 34, pp. 337-343, (1994)

[3]

Dahlof C.G.H., Dimenas E., Migraine patients experience poorer subjective well-being/quality of life even between attacks, Cephalalgia, 15, pp. 31-36, (1995)

[4]

Bussone G., Usai S., Grazzi L., Rigamonti A., Solari A., D'Amico D., Disability and quality of life in different primary headaches: Results from Italian studies, Neurol. Sci., 25, SUPPL. 3, (2004)

[5]

Menken M., Munsat T.L., Toole J.F., The Global Burden of Disease Study: Implications for neurology, Arch. Neurol., 57, pp. 418-420, (2000)

[6]

Schipper H., Why measure quality of life?, Can. Med. Assoc. J., 128, pp. 1367-1370, (1983)

[7]

Carr A.J., Gibson B., Robinson P.G., Is quality of life determined by expectations or experience?, BMJ, 322, pp. 1240-1243, (2001)

[8]

Patrick L.D., Deyo R.A., Generic and disease-specific measures in assessing health status and quality of life, Med. Care, 27, (1989)

[9]

Bayley B.K., London M.R., Grunkemeier G.L., Lansky D., Measuring the success of treatment in patient terms, Med. Care, 33, (1995)

[10]

Santanello N.C., Polis A.B., Hartmaier S.L., Kramer M.S., Block G.A., Silberstein S.D., Improvement in migraine-specific quality of life in a clinical trial of rizatriptan, Cephalalgia, 17, pp. 867-872, (1997)

← 1 2 3 →